Hawinkels L J A C, Verspaget H W, van Duijn W, van der Zon J M, Zuidwijk K, Kubben F J G M, Verheijen J H, Hommes D W, Lamers C B H W, Sier C F M
Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
Br J Cancer. 2007 Aug 6;97(3):398-404. doi: 10.1038/sj.bjc.6603877. Epub 2007 Jul 17.
Transforming growth factor-beta1 (TGF-beta1), a tumour suppressing as well as tumour-promoting cytokine, is stored as an extracellular matrix-bound latent complex. We examined TGF-beta1 activation and localisation of TGF-beta1 activity in gastric cancer. Gastric tumours showed increased stromal and epithelial total TGF-beta1 staining by immunohistochemistry. Active TGF-beta1 was present in malignant epithelial cells, but most strongly in smooth muscle actin expressing fibroblasts. Normal gastric mucosa from the same patient showed some staining for total, and little for active TGF-beta1. Active TGF-beta1 levels were determined by ELISA on tissue homogenates, confirming a strong increase in active TGF-beta1 in tumours compared to corresponding normal mucosa. Moreover, high tumour TGF-beta1 activity levels were significantly associated with clinical parameters, including worse survival of the patients. Total and active TGF-beta1 levels were not correlated, suggesting a specific activation process. Of the different proteases tested, active TGF-beta1 levels were only correlated with urokinase activity levels. The correlation with urokinase activity suggests a role for plasmin in TGF-beta1 activation in the tumour microenvironment, resulting in transformation of resident fibroblasts to tumour promoting myofibroblasts. In conclusion we have shown localisation and clinical relevance of TGF-beta1 activity levels in gastric cancer.
转化生长因子-β1(TGF-β1)是一种具有肿瘤抑制和肿瘤促进作用的细胞因子,以细胞外基质结合的潜伏复合物形式储存。我们研究了胃癌中TGF-β1的激活及其活性的定位。免疫组织化学显示,胃肿瘤的基质和上皮中总TGF-β1染色增加。活性TGF-β1存在于恶性上皮细胞中,但在表达平滑肌肌动蛋白的成纤维细胞中最为强烈。同一患者的正常胃黏膜显示出一些总TGF-β1染色,而活性TGF-β1染色很少。通过对组织匀浆进行ELISA测定活性TGF-β1水平,证实与相应的正常黏膜相比,肿瘤中活性TGF-β1显著增加。此外,肿瘤TGF-β1高活性水平与临床参数显著相关,包括患者较差的生存率。总TGF-β1水平与活性TGF-β1水平不相关,提示存在特定的激活过程。在所测试的不同蛋白酶中,活性TGF-β1水平仅与尿激酶活性水平相关。与尿激酶活性的相关性表明纤溶酶在肿瘤微环境中TGF-β1激活中起作用,导致驻留成纤维细胞转化为肿瘤促进性肌成纤维细胞。总之,我们已经证明了TGF-β1活性水平在胃癌中的定位及其临床相关性。